ATC Group: A10AB Insulins and analogues for injection, fast-acting

Anatomical Therapeutic Chemical Classification System

Translations

Language
Translation
  English
Insulins and analogues for injection, fast-acting

Hierarchical Position

Level
Code
Title
4
A10AB
Insulins and analogues for injection, fast-acting

Contents

Code
Title
A10AB01
A10AB02
A10AB03
A10AB04
A10AB05
A10AB30

Active Ingredients

Chemical substance
Description

The blood glucose lowering effect of insulin is due to the facilitated uptake of glucose following binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver.

The blood glucose lowering effect of insulin aspart is due to the facilitated uptake of glucose following binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver. Insulin aspart produces a more rapid onset of action compared to soluble human insulin, together with a lower glucose concentration, as assessed within the first four hours after a meal. Insulin aspart has a shorter duration of action compared to soluble human insulin after subcutaneous injection.

Insulin glulisine is a recombinant human insulin analogue that is equipotent to regular human insulin. Insulin glulisine has a more rapid onset of action and a shorter duration of action than regular human insulin.

The primary activity of insulin lispro is the regulation of glucose metabolism.